Business
Nanotechnology Research Collaboration with Universidad de Sevilla to Create Time-Released Formulation for GB Sciences' THC-Free Chronic Pain Therapy
Nanotechnology Research Collaboration with Universidad de Sevilla to Create Time-Released Formulation for GB Sciences' THC-Free Chronic Pain Therapy.
About this update from Gb Sciences, Inc.
[{"type":"text","content":"\n\n\n\nNanotechnology Research Collaboration with Universidad de Sevilla to Create Time-Released Formulation for GB Sciences' THC-Free Chronic Pain Therapy\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nNanotechnology Research Collaboration with Universidad de Sevilla to Create Time-Released Formulation for GB Sciences' THC-Free Chronic Pain Therapy\nPR Newswire\nLAS VEGAS, Oct. 10, 2017\n\n\n\nLAS VEGAS, Oct. 10, 2017 /PRNewswire/ -- GB Sciences, Inc. (OTCQB: GBLX) has entered into a Contract Research Agreement with the Universidad de Sevilla (\"USE\") to develop a time-released version of GB Sciences' proprietary, THC-free, myrcene-based chronic pain formulations. \n\n\n \n \n\n \nGB Sciences has identified USE as having top-notch nanotechnology experts, excellent research facilities, and state-of-the art scientific equipment. The group working with GB Sciences on this important project is headed by Dr. Mercedes Fernández Arévalo and Dr. Lucia Martin Banderas. \n\n\"Our research group has been diligently working on the development of new oral drug delivery systems. We design nanometric systems able to offer the greatest control and effectiveness of the drug taking into account physicochemical and biopharmaceutical drug properties. This is the case of our recently developed cannabinoid nanosystems. More recently, we were involved in the development of nanosystems intended to actively target specific diseases, which involves developing more complex nanosystems with highly specific surface properties,\" said Dr. Mercedes Fernández Arévalo (I+DNanomed, Website: grupos.us.es/idnanomed/).\n\nIn May of 2017, GB Sciences filed a provisional patent application for myrcene-containing complex mixtures for chronic pain relief (among other uses). GB Sciences is now collaborating with USE to develop a suitable nanotech-based delivery mechanism that would provide a steady release of active ingredients over time, which is very desirable for chronic conditions.\n\n\"Some patients who need relief from chronic pain, do not want the psychoactive effects of THC found ...